ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
7 hedge funds and large institutions have $6.48M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
7% less capital invested
Capital invested by funds: $6.97M → $6.48M (-$497K)
22% less funds holding
Funds holding: 9 → 7 (-2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$27.4K |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$19.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$84.2K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$58K |
| 3 |
Millennium Management
New York
|
-$37K |
| 4 |
Morgan Stanley
New York
|
-$12.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Temasek Holdings
Singapore
| $2.7M | – | – | – |
|
|
SCM
2
Sio Capital Management
New York
| $2.62M | – | – | – |
|
|
PIM
3
Platinum Investment Management
Sydney Australia 2000,
Australia
| $812K | +$19.7K | +293 | +3% |
|
|
DCM
4
DAFNA Capital Management
Los Angeles,
California
| $164K | – | – | – |
|
|
5
Renaissance Technologies
New York
| $148K | -$84.2K | -1,253 | -39% |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $31K | +$27.4K | +408 | New |
|
|
7
Morgan Stanley
New York
| $3K | -$12.6K | -188 | -80% |
|
|
8
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$58K | -750 | Closed |
|
|
9
Millennium Management
New York
| – | -$37K | -477 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$3K | -37 | Closed |
|
ASLN Hedge Fund Activity: Q3 2020 in Review
7 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q3 2020, worth a combined $6.48M — down 7.1% from $6.97M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ASLN and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $27.4K. The largest seller was Renaissance Technologies, cutting an estimated $84.2K.
- 7 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q3 2020, down from 9 in Q2 2020.
- Funds reported $6.48M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q3 2020, down 7.1% quarter-over-quarter.
- 1 fund opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q3 2020 and 3 closed out, a net change of -2 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q3 2020 was Susquehanna International Group, an estimated $27.4K added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q3 2020 was Renaissance Technologies, an estimated $84.2K sold.
Based on aggregated 13F filings for Q3 2020.